Utilization — not cost growth — continues to accelerate spending, government actuaries said. Spiking prescription drug spending, including on GLP-1s, is especially acute.
Utilization — not cost growth — continues to accelerate spending, government actuaries said. Spiking prescription drug spending, including on GLP-1s, is especially acute.
